Genetic Polymorphism of Interleukin-1A (IL-1A), IL-1B, and IL-1 Receptor Antagonist (IL-1RN) and Prostate Cancer Risk

  • Xu, Hua (Department of Urology, Huashan Hospital, Fudan University) ;
  • Ding, Qiang (Department of Urology, Huashan Hospital, Fudan University) ;
  • Jiang, Hao-Wen (Department of Urology, Huashan Hospital, Fudan University)
  • Published : 2014.11.06


Purpose: We aimed to investigate the associations between polymorphisms of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer (PCa) risk. Materials and Methods: A comprehensive search for articles of MEDLINE and EMBASE databases and bibliographies of retrieved articles published up to August 3, 2014 was performed. Methodological quality assessment of the trials was based on a standard quality scoring system. The meta-analysis was performed using STATA 12.0. Results: We included 9 studies (1 study for IL-1A, 5 studies for IL-1B, and 3 studies for IL-1RN), and significant association was found between polymorphisms of IL-1B-511 (rs16944) as well as IL-1B-31 (rs1143627) and PCa risk. IL-1B-511 (rs16944) polymorphism was significantly associated with PCa risk in homozygote and recessive models, as well as allele contrast (TT vs CC: OR, 0.74; 95%CI, 0.58-0.94; P=0.012; TT vs TC+CC; OR, 0.79; 95%CI, 0.63-0.98; P=0.033; T vs C: OR, 0.86; 95%CI, 0.77-0.96; P=0.008). The association between IL-1B-31 (rs1143627) polymorphism and PCa risk was weakly significant under a heterozygote model (OR, 1.35; 95%CI, 1.00-1.80; P=0.047). Conclusions: Sequence variants in IL-1B-511 (rs16944) and IL-1B-31 (rs1143627) are significantly associated with PCa risk, which provides additional novel evidence that proinflammatory cytokines and inflammation play an important role in the etiology of PCa.


  1. Apte RN, Voronov E (2008). Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev, 222, 222-41.
  2. Baker SG, Lichtenstein P, Kaprio J, et al (2005). Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins. Biometrics, 61, 55-63.
  3. Bradley JR, Pober JS (2001). Tumor necrosis factor receptorassociated factors (TRAFs). Oncogene, 20, 6482-91.
  4. Cheng I, Krumroy LM, Plummer SJ, et al (2007). MIC1 and IL1RN genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 16, 1309-11.
  5. Dinarello CA (1988). Biology of interleukin 1. FASEB J, 2, 108-15.
  6. Dal Moro F, Zattoni F (2013). Inflammation and prostate cancer. Urol Oncol, 31, 712.
  7. Dennis LK, Lynch CF, Torner JC (2002). Epidemiologic association between prostatitis and prostate cancer. Urology, 60, 78-83.
  8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  9. Dluzniewski PJ, Wang MH, Zheng SL, et al (2012). Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev, 21, 1774-82.
  10. Domingo-Domenech J, Oliva C, Rovira A, et al (2006). Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res, 12, 5578-86.
  11. Dwivedi S, Goel A, Natu SM, et al (2011). Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. Asian Pac J Cancer Prev, 12, 1843-8.
  12. Eeles R, Goh C, Castro E, et al (2014). The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol, 11, 18-31.
  13. El-Omar EM, Carrington M, Chow WH, et al (2000). Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 404, 398-402.
  14. Guo YZ, Pan L, Du CJ, et al (2013). Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev, 14, 243-8.
  15. Jim HS, Park JY, Permuth-Wey J, et al (2012). Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings. Brain Behav Immun, 26, 1030-6.
  16. Guttridge DC, Albanese C, Reuther JY, et al (1999). NFkappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol, 19, 5785-99.
  17. Hollegaard MV, Bidwell JL (2006). Cytokine gene polymorphism in human disease: on-line databases, Supplement 3. Genes Immun, 7, 269-76.
  18. Iwanaga R, Ozono E, Fujisawa J, et al (2008). Activation of the cyclin D2 and cdk6 genes through NF-kappaB is critical for cell-cycle progression induced by HTLV-I Tax. Oncogene, 27, 5635-42.
  19. Lindmark F, Zheng SL, Wiklund F, et al (2005). Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer, 93, 493-7.
  20. Ma L, Zhao J, Li T, et al (2014). Association between Tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol, 9, 74.
  21. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  22. McCarron SL, Edwards S, Evans PR, et al (2002). Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res, 62, 3369-72.
  23. McIntyre KW, Stepan GJ, Kolinsky KD, et al (1991). Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med, 173, 931-9.
  24. Ricote M, Garcia-Tunon I, Bethencourt FR, et al (2004). Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer, 100, 1388-96.
  25. Michaud DS, Daugherty SE, Berndt SI, et al (2006). Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res, 66, 4525-30.
  26. Nguyen DP, Li J, Yadav SS, et al (2014). Recent insights into NF-kappaB signalling pathways and the link between inflammation and prostate cancer. BJU Int, 114, 168-76.
  27. Patel DA, Bock CH, Schwartz K, et al (2005). Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case--control study in Wayne County, Michigan. Cancer Causes Control, 16, 263-73.
  28. Saenz-Lopez P, Carretero R, Cozar JM, et al (2008). Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 8, 382.
  29. Shao N, Xu B, Mi YY, et al (2011). IL-10 polymorphisms and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis, 14, 129-35.
  30. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
  31. Thakkinstian A, McEvoy M, Minelli C, et al (2005). Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol, 162, 201-11.
  32. Vignozzi L, Maggi M (2014). Prostate cancer: Intriguing data on inflammation and prostate cancer. Nat Rev Urol, 11, 369-70.
  33. Wang MH, Helzlsouer KJ, Smith MW, et al (2009). Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate, 69, 874-85.
  34. Yamamoto-Furusho JK, Santiago-Hernandez JJ, Perez-Hernandez N, et al (2011). Interleukin 1 beta (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitis. J Clin Gastroenterol, 45, 531-5.
  35. Wang N, Zhou R, Wang C, et al (2012). -251 T/A polymorphism of the interleukin-8 gene and cancer risk: a HuGE review and meta-analysis based on 42 case-control studies. Mol Biol Rep, 39, 2831-41.
  36. Wang Y, Kato N, Hoshida Y, et al (2003). Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology, 37, 65-71.
  37. Xu J, Lowey J, Wiklund F, et al (2005). The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 14, 2563-8.
  38. Yang HP, Woodson K, Taylor PR, et al (2006). Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. Eur J Cancer Prev, 15, 249-53.
  39. Yang M, Li C, Li M (2014). Association of interleukin-6 (-174 G/C) polymorphism with the prostate cancer risk: A metaanalysis. Biomed Rep, 2, 637-43.
  40. Yu Z, Liu Q, Huang C, et al (2013). The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and metaanalysis of 73 studies including 15,942 cases and 22,336 controls. OMICS, 17, 200-14.
  41. Zabaleta J, Lin HY, Sierra RA, et al (2008). Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 29, 573-8.
  42. Zabaleta J, Su LJ, Lin HY, et al (2009). Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis, 30, 1358-62.
  43. Zhang J, Dhakal IB, Lang NP, et al (2010). Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk. Cancer Causes Control, 21, 1437-44.
  44. Zienolddiny S, Ryberg D, Maggini V, et al (2004). Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer, 109, 353-6.

Cited by

  1. IL-1β Polymorphism and Expression Associated with Decreased Risk of Gastric Carcinoma: a Case Control Study in the Ethnic Kashmiri Population, India vol.16, pp.5, 2015,
  2. A novel anticancer agent icaritin inhibited proinflammatory cytokines in TRAMP mice vol.48, pp.10, 2016,
  3. Detection, quantification, and profiling of PSA: current microarray technologies and future directions vol.6, pp.9, 2016,
  4. Detection of lncRNA-mRNA interaction modules by integrating eQTL with weighted gene co-expression network analysis pp.1438-7948, 2018,
  5. Association between IL-1RN VNTR polymorphism and head and neck cancer in Indonesian population vol.1073, pp.1742-6596, 2018,
  6. The Genetic Polymorphisms of NLRP3 Inflammasome Associated with T Helper Cells in Patients with Multiple Myeloma vol.2018, pp.2314-7156, 2018,
  7. Interleukin-1 Beta—A Friend or Foe in Malignancies? vol.19, pp.8, 2018,